Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:NWBONASDAQ:SAGENASDAQ:SIGAOTCMKTS:TBUFF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNWBONorthwest Biotherapeutics$0.28-2.9%$0.26$0.17▼$0.50$397.36M-0.813.85 million shs2.84 million shsSAGESage Therapeutics$6.53-1.2%$7.32$4.62▼$13.47$408.92M0.21.19 million shs770,577 shsSIGASIGA Technologies$5.91+1.2%$5.82$4.95▼$12.83$422.22M0.92732,354 shs479,585 shsTBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNWBONorthwest Biotherapeutics+5.44%-1.21%-1.62%+16.20%-37.59%SAGESage Therapeutics-2.79%0.00%-13.93%-9.58%-45.37%SIGASIGA Technologies-4.73%-1.35%-4.73%-1.18%-21.93%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNWBONorthwest Biotherapeutics0.2105 of 5 stars0.05.00.00.00.00.00.0SAGESage Therapeutics3.8353 of 5 stars3.02.00.04.02.71.71.3SIGASIGA Technologies1.3792 of 5 stars0.01.00.00.02.20.83.1TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNWBONorthwest Biotherapeutics 0.00N/AN/AN/ASAGESage Therapeutics 2.00Hold$8.8134.95% UpsideSIGASIGA Technologies 0.00N/AN/AN/ATBUFFTribute Pharmaceuticals Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TBUFF, SIGA, SAGE, and NWBO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/11/2025SAGESage TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$5.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNWBONorthwest Biotherapeutics$1.93M205.89N/AN/A($0.06) per share-4.61SAGESage Therapeutics$47.40M8.63N/AN/A$7.56 per share0.86SIGASIGA Technologies$120.33M3.51$0.93 per share6.34$2.77 per share2.13TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNWBONorthwest Biotherapeutics-$62.60M-$0.07N/A∞N/A-4,666.29%N/A-261.36%8/7/2025 (Estimated)SAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-971.50%-68.18%-60.84%7/30/2025 (Estimated)SIGASIGA Technologies$68.07M$0.674.934.73N/A49.33%49.06%38.72%8/7/2025 (Estimated)TBUFFTribute Pharmaceuticals CanadaN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest TBUFF, SIGA, SAGE, and NWBO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025NWBONorthwest BiotherapeuticsN/A-$0.01N/A-$0.01N/A$0.38 million5/8/2025Q1 2025SIGASIGA TechnologiesN/A-$0.01N/A-$0.01N/A$7.04 million4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million3/31/2025Q4 2024NWBONorthwest BiotherapeuticsN/A-$0.02N/A-$0.02N/A$0.23 million3/11/2025Q4 2024SIGASIGA TechnologiesN/A$0.63N/A$0.63N/A$81.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/ALatest TBUFF, SIGA, SAGE, and NWBO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/8/2025SIGASIGA Technologiesspecial$0.604/29/20254/29/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNWBONorthwest BiotherapeuticsN/A0.090.09SAGESage TherapeuticsN/A7.427.42SIGASIGA TechnologiesN/A8.105.32TBUFFTribute Pharmaceuticals CanadaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNWBONorthwest Biotherapeutics0.04%SAGESage Therapeutics99.22%SIGASIGA Technologies55.40%TBUFFTribute Pharmaceuticals CanadaN/AInsider OwnershipCompanyInsider OwnershipNWBONorthwest Biotherapeutics8.70%SAGESage Therapeutics5.50%SIGASIGA Technologies1.54%TBUFFTribute Pharmaceuticals CanadaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNWBONorthwest Biotherapeutics201.44 billion1.24 billionNot OptionableSAGESage Therapeutics69062.62 million58.10 millionOptionableSIGASIGA Technologies4071.44 million70.31 millionOptionableTBUFFTribute Pharmaceuticals CanadaN/A113.72 millionN/ANot OptionableTBUFF, SIGA, SAGE, and NWBO HeadlinesRecent News About These CompaniesSimone Biles pays tribute to husband Jonathan Owens with tiny new tattooSeptember 21, 2024 | pagesix.comKid Rock's Toby Keith Tribute Concert Broke Taylor Swift's Audience Record?September 14, 2024 | snopes.comTRANSFORMERS ONE - Advance Screening & Prize Pack ContestSeptember 12, 2024 | tribute.caCate Blanchett Calls For Sustainability In Film Industry At TIFF Tribute Awards: “There Is A Moral Imperative To Make This Switch”September 11, 2024 | deadline.comInside the TIFF Tribute Awards: Angelina Jolie Asks for No Photographs and Viggo Mortensen Decries David Cronenberg’s Oscar SnubsSeptember 11, 2024 | variety.comTIFF 2024: Tragically Hip series honors beloved Canadian bandSeptember 6, 2024 | reuters.comTop country stars honor Toby Keith in a new special. Here's how to watchSeptember 2, 2024 | today.com‘Survivor’s Remorse’ actress Erica Ash dead at 46: Loni Love, Bow Wow and more pay tributeJuly 31, 2024 | pagesix.comValeo Pharma Inc. (VPHIF)May 17, 2024 | finance.yahoo.comAbout Tribute.caApril 1, 2024 | tribute.caMacGregor: A Remembrance Day tribute to Canada's Korean War veteransNovember 13, 2023 | ottawacitizen.comChurch Under Fire: Canada's War on Christianity - CastOctober 25, 2023 | tribute.caTerry Funk dies, aged 79: Pro wrestling industry pays tribute to hardcore iconAugust 27, 2023 | sportingnews.comRon Canada Biography & MoviesJuly 23, 2023 | tribute.caWhen her brother died, she wrote a moving tribute on a frisbee. Now, his memory is being shared from one city to the next.May 2, 2023 | yahoo.comAlberta tattoo artists pay tribute to laser removal expert who helped people move past traumaApril 29, 2023 | cbc.caMITSUBISHI TANABE PHARMA CANADA RECEIVES ENGAGEMENT LETTER FROM PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR RADICAVA® ORAL SUSPENSIONApril 27, 2023 | finance.yahoo.comHumboldt holds tribute five years after deadly bus crashApril 8, 2023 | thestar.comPaul O’Grady fans break down in tears over Lily Savage’s Blankety Blank tribute episode after shock deathApril 3, 2023 | thesun.co.ukGamer Crochets Destiny 2 Tribute to Zavalla Actor Lance ReddickApril 3, 2023 | gamerant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBUFF, SIGA, SAGE, and NWBO Company DescriptionsNorthwest Biotherapeutics OTCMKTS:NWBO$0.28 -0.01 (-2.88%) As of 03:59 PM EasternNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Sage Therapeutics NASDAQ:SAGE$6.53 -0.08 (-1.21%) Closing price 04:00 PM EasternExtended Trading$6.66 +0.13 (+1.99%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.SIGA Technologies NASDAQ:SIGA$5.91 +0.07 (+1.20%) Closing price 04:00 PM EasternExtended Trading$5.99 +0.08 (+1.42%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.Tribute Pharmaceuticals Canada OTCMKTS:TBUFFTribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
